Literature DB >> 20213343

Cyclic GMP and nitric oxide synthase in aging and Alzheimer's disease.

Katarzyna Urszula Domek-Łopacińska1, Joanna B Strosznajder.   

Abstract

Cyclic guanosine monophosphate (cGMP) is an important secondary messenger synthesized by the guanylyl cyclases which are found in the soluble (sGC) and particular isoforms. In the central nervous system, the nitric oxide (NO)-sensitive sGC isoform is the major enzyme responsible for cGMP synthesis. Phosphodiesterases (PDEs) are enzymes for hydrolysis of cGMP in the brain, and they are mainly isoforms 2, 5, and 9. The NO/cGMP signaling pathway has been shown to play an important role in the process underlying learning and memory. Aging is associated with an increase in PDE expression and activity and a decrease in cGMP concentration. In addition, aging is also associated with an enhancement of neuronal NO synthase, a lowering of endothelial, and no alteration in inducible activity. The observed changes in NMDA receptor density along with the Ca(2+)/NO/cGMP pathway underscore the lower synaptic plasticity and cognitive performance during aging. This notion is in agreement with last data indicating that inhibitors of PDE2 and PDE9 improve learning and memory in older rats. In this review, we focus on recent studies supporting the role of Ca(2+)/NO/cGMP pathway in aging and Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20213343     DOI: 10.1007/s12035-010-8104-x

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  61 in total

1.  Beta-amyloid plaques induce neuritic dystrophy of nitric oxide-producing neurons in a transgenic mouse model of Alzheimer's disease.

Authors:  J Quinn; F Davis; W R Woodward; F Eckenstein
Journal:  Exp Neurol       Date:  2001-04       Impact factor: 5.330

2.  Nitric oxide synthase neurons in different areas of normal aged and Alzheimer's brains.

Authors:  D T Yew; H W Wong; W P Li; H W Lai; W H Yu
Journal:  Neuroscience       Date:  1999-03       Impact factor: 3.590

3.  Inhibition of Alzheimer's beta-amyloid induced vasoactivity and proinflammatory response in microglia by a cGMP-dependent mechanism.

Authors:  D Paris; T Town; T A Parker; J Tan; J Humphrey; F Crawford; M Mullan
Journal:  Exp Neurol       Date:  1999-05       Impact factor: 5.330

4.  Regional and age-dependent expression of the nitric oxide receptor, soluble guanylyl cyclase, in the human brain.

Authors:  C Ibarra; P I Nedvetsky; M Gerlach; P Riederer; H H Schmidt
Journal:  Brain Res       Date:  2001-07-13       Impact factor: 3.252

5.  The function of the glutamate-nitric oxide-cGMP pathway in brain in vivo and learning ability decrease in parallel in mature compared with young rats.

Authors:  Blanca Piedrafita; Omar Cauli; Carmina Montoliu; Vicente Felipo
Journal:  Learn Mem       Date:  2007-04-05       Impact factor: 2.460

6.  Activation of constitutive nitric oxide synthase(s) and absence of inducible isoform in aged rat brain.

Authors:  Henryk Jesko; Malgorzata Chalimoniuk; Joanna B Strosznajder
Journal:  Neurochem Int       Date:  2003-03       Impact factor: 3.921

7.  A reversal by L-arginine and sodium nitroprusside of ageing-induced memory impairment in rats by increasing nitric oxide concentration in the hippocampus.

Authors:  Vanaja Paul; Leema Reddy; P Ekambaram
Journal:  Indian J Physiol Pharmacol       Date:  2005-04

8.  S-nitrosylation of Drp1 mediates beta-amyloid-related mitochondrial fission and neuronal injury.

Authors:  Dong-Hyung Cho; Tomohiro Nakamura; Jianguo Fang; Piotr Cieplak; Adam Godzik; Zezong Gu; Stuart A Lipton
Journal:  Science       Date:  2009-04-03       Impact factor: 47.728

9.  Expression of the cGMP-specific phosphodiesterases 2 and 9 in normal and Alzheimer's disease human brains.

Authors:  Elisabet Reyes-Irisarri; Marjanne Markerink-Van Ittersum; Guadalupe Mengod; Jan de Vente
Journal:  Eur J Neurosci       Date:  2007-06       Impact factor: 3.386

Review 10.  Concepts of neural nitric oxide-mediated transmission.

Authors:  John Garthwaite
Journal:  Eur J Neurosci       Date:  2008-06       Impact factor: 3.386

View more
  26 in total

Review 1.  Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments.

Authors:  Thérèse Keravis; Claire Lugnier
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

2.  Age-related changes in nitric oxide activity, cyclic GMP, and TBARS levels in platelets and erythrocytes reflect the oxidative status in central nervous system.

Authors:  Elisa Mitiko Kawamoto; Andrea Rodrigues Vasconcelos; Sabrina Degaspari; Ana Elisa Böhmer; Cristoforo Scavone; Tania Marcourakis
Journal:  Age (Dordr)       Date:  2012-01-26

Review 3.  Nitric oxide signalling in the brain and its control of bodily functions.

Authors:  Konstantina Chachlaki; Vincent Prevot
Journal:  Br J Pharmacol       Date:  2019-09-08       Impact factor: 8.739

4.  The Phosphodiesterase 9 Inhibitor PF-04449613 Promotes Dendritic Spine Formation and Performance Improvement after Motor Learning.

Authors:  Baoling Lai; Miao Li; Wanling Hu; Wei Li; Wen-Biao Gan
Journal:  Dev Neurobiol       Date:  2018-07-18       Impact factor: 3.964

Review 5.  Clinical and molecular genetics of the phosphodiesterases (PDEs).

Authors:  Monalisa F Azevedo; Fabio R Faucz; Eirini Bimpaki; Anelia Horvath; Isaac Levy; Rodrigo B de Alexandre; Faiyaz Ahmad; Vincent Manganiello; Constantine A Stratakis
Journal:  Endocr Rev       Date:  2013-12-05       Impact factor: 19.871

6.  Endothelial nitric oxide deficiency promotes Alzheimer's disease pathology.

Authors:  Susan A Austin; Anantha V Santhanam; David J Hinton; Doo-Sup Choi; Zvonimir S Katusic
Journal:  J Neurochem       Date:  2013-06-27       Impact factor: 5.372

7.  Human chromosome 21 orthologous region on mouse chromosome 17 is a major determinant of Down syndrome-related developmental cognitive deficits.

Authors:  Li Zhang; Kai Meng; Xiaoling Jiang; Chunhong Liu; Annie Pao; Pavel V Belichenko; Alexander M Kleschevnikov; Sheena Josselyn; Ping Liang; Ping Ye; William C Mobley; Y Eugene Yu
Journal:  Hum Mol Genet       Date:  2013-09-16       Impact factor: 6.150

8.  Synthesis of quinoline derivatives: discovery of a potent and selective phosphodiesterase 5 inhibitor for the treatment of Alzheimer's disease.

Authors:  Jole Fiorito; Faisal Saeed; Hong Zhang; Agnieszka Staniszewski; Yan Feng; Yitshak I Francis; Sudha Rao; Devarshi M Thakkar; Shi-Xian Deng; Donald W Landry; Ottavio Arancio
Journal:  Eur J Med Chem       Date:  2012-12-14       Impact factor: 6.514

9.  Psychostimulant pharmacological profile of paraxanthine, the main metabolite of caffeine in humans.

Authors:  Marco Orrú; Xavier Guitart; Marzena Karcz-Kubicha; Marcello Solinas; Zuzana Justinova; Sandeep Kumar Barodia; Janaina Zanoveli; Antoni Cortes; Carme Lluis; Vicent Casado; F Gerard Moeller; Sergi Ferré
Journal:  Neuropharmacology       Date:  2012-12-19       Impact factor: 5.250

10.  Effects of restraint stress and nitric oxide synthase inhibition on learning and strategy preference in young adult male rats.

Authors:  Melih Dağdeviren; Yusuf Hakan Doğan; Lütfiye Kanıt
Journal:  Balkan Med J       Date:  2012-12-01       Impact factor: 2.021

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.